RxDoctor Payments Data

Jonathan Heinlen, MD

Urology · Oklahoma City, OKNPI 1275739856

Payments from drug & device makers

$5,097in general payments, 2019–2025

Across 43 payments — averaging $118.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • Stryker$464
  • Urogen Pharma, Inc.$286
  • Dendreon Pharmaceuticals LLC$256
  • Coloplast$237
  • Astellas Pharma Global Development$202
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$2,48449%
  • Travel & lodging$4379%
  • Food & beverage$2,00839%
  • Education$1683%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,097 in reported general payments places this provider in the 55th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$173,086
Medicare patients
550
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide20$250,749
Abiraterone Acetate102$183,754
OrgovyxRelugolix23$61,931
MyrbetriqMirabegron46$32,469
GemtesaVibegron15$10,798
Tamsulosin Hcl375$5,088
Estradiol44$3,807
Tadalafil16$3,356
Silodosin40$3,129
Solifenacin Succinate76$2,700
Finasteride174$2,192
Methenamine Hippurate18$1,780
Testosterone Cypionate42$1,081
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$506
Dutasteride17$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$88$32,46946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 145 urology providers in Oklahoma.

Other urology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →